- Home
- GNRC vs PCVX Comparison
GNRC vs PCVX Comparison
Compare GNRC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNRC
- PCVX
- Stock Information
- Founded
- GNRC 1959
- PCVX 2013
- Country
- GNRC United States
- PCVX United States
- Employees
- GNRC N/A
- PCVX N/A
- Industry
- GNRC Metal Fabrications
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- GNRC Consumer Discretionary
- PCVX Health Care
- Exchange
- GNRC Nasdaq
- PCVX Nasdaq
- Market Cap
- GNRC 7.5B
- PCVX 4.4B
- IPO Year
- GNRC 2010
- PCVX 2020
- Fundamental
- Price
- GNRC $146.73
- PCVX $33.10
- Analyst Decision
- GNRC Buy
- PCVX Strong Buy
- Analyst Count
- GNRC 18
- PCVX 10
- Target Price
- GNRC $170.72
- PCVX $136.50
- AVG Volume (30 Days)
- GNRC 1.0M
- PCVX 1.5M
- Earning Date
- GNRC 07-30-2025
- PCVX 08-05-2025
- Dividend Yield
- GNRC N/A
- PCVX N/A
- EPS Growth
- GNRC 58.27
- PCVX N/A
- EPS
- GNRC 5.74
- PCVX N/A
- Revenue
- GNRC $4,348,682,000.00
- PCVX N/A
- Revenue This Year
- GNRC $5.47
- PCVX N/A
- Revenue Next Year
- GNRC $6.75
- PCVX N/A
- P/E Ratio
- GNRC $24.95
- PCVX N/A
- Revenue Growth
- GNRC 8.07
- PCVX N/A
- 52 Week Low
- GNRC $99.50
- PCVX $27.66
- 52 Week High
- GNRC $195.94
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- GNRC 76.10
- PCVX 42.61
- Support Level
- GNRC $123.94
- PCVX $32.06
- Resistance Level
- GNRC $143.70
- PCVX $33.81
- Average True Range (ATR)
- GNRC 3.44
- PCVX 1.23
- MACD
- GNRC 1.73
- PCVX -0.16
- Stochastic Oscillator
- GNRC 95.18
- PCVX 8.44
About GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.